International Circulation:  That last part you mentioned seems relevant since this is a Chinese publication.  As a journal from China with a predominantly Asian readership， it is of importance that we can apply this combination therapy to Asian populations such as in China， Japan， or other Asian countries. 

国际循环：刚刚提到的似乎与中国有关。这种联合疗法能否应用到中国、日本等亚洲人群？

Michael Weber:  Our experience would fit very well in the Asian countries， China， Japan， Korea， and so forth.  What is very interesting is that， I believe， for many patients in those countries the use of amlodipine， for example， has already been shown to be very beneficial in a number of important outcome studies.  So the combination with a blocker of the renin/angiotensin system and， I suspect， it is going to be more the use of a renin/angiotensin receptor blocker rather than an ACE inhibitor because the renin/angiotensin receptor blockers do not have the problem of cough that is so common among Asian patients taking ACE inhibitors.  I suspect the combination of a renin/angiotensin receptor blocker plus amlodipine is going to be very popular in China， Japan， and other Asian countries. 

Michael Weber教授：该试验结果完全适用于亚洲国家，如中国、日本、韩国等。已证实，氨氯地平对这些地区患者有益。与肾素/血管紧张素系统阻断剂联合将比与ACE抑制剂联合更普遍有效，因为它没有服用ACE抑制剂造成的咳嗽现象。我认为，肾素/血管紧张素系统阻断剂联合氨氯地平将推广于中国、日本和其他亚洲国家。